Amundi lifted its stake in shares of Balchem Co. (NASDAQ:BCPC – Free Report) by 151.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,096 shares of the basic materials company’s stock after acquiring an additional 11,496 shares during the quarter. Amundi’s holdings in Balchem were worth $3,000,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also modified their holdings of the company. Watts Gwilliam & Co. LLC increased its position in shares of Balchem by 63.7% during the fourth quarter. Watts Gwilliam & Co. LLC now owns 35,069 shares of the basic materials company’s stock worth $5,438,000 after acquiring an additional 13,642 shares during the period. JPMorgan Chase & Co. increased its position in shares of Balchem by 1.7% during the third quarter. JPMorgan Chase & Co. now owns 458,986 shares of the basic materials company’s stock worth $80,782,000 after acquiring an additional 7,721 shares during the period. Stifel Financial Corp increased its position in shares of Balchem by 26.2% during the third quarter. Stifel Financial Corp now owns 11,893 shares of the basic materials company’s stock worth $2,093,000 after acquiring an additional 2,467 shares during the period. Apollon Wealth Management LLC purchased a new stake in shares of Balchem during the fourth quarter worth $503,000. Finally, Congress Asset Management Co. increased its holdings in Balchem by 5.4% in the fourth quarter. Congress Asset Management Co. now owns 317,610 shares of the basic materials company’s stock valued at $51,769,000 after buying an additional 16,170 shares during the last quarter. Hedge funds and other institutional investors own 87.91% of the company’s stock.
Balchem Stock Performance
NASDAQ:BCPC opened at $167.72 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.99 and a quick ratio of 1.16. Balchem Co. has a 12 month low of $137.69 and a 12 month high of $186.03. The firm has a market capitalization of $5.46 billion, a PE ratio of 42.68, a price-to-earnings-growth ratio of 4.41 and a beta of 0.63. The business’s fifty day moving average price is $163.84 and its 200 day moving average price is $169.73.
Analysts Set New Price Targets
BCPC has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $190.00 target price on shares of Balchem in a report on Monday, February 24th. StockNews.com lowered Balchem from a “buy” rating to a “hold” rating in a report on Tuesday, February 25th. Finally, Sidoti raised Balchem to a “hold” rating in a report on Tuesday, February 25th.
Check Out Our Latest Analysis on Balchem
Balchem Profile
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Featured Stories
- Five stocks we like better than Balchem
- How is Compound Interest Calculated?
- How to Build the Ultimate Everything ETF Portfolio
- Market Cap Calculator: How to Calculate Market Cap
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Stock Dividend Cuts Happen Are You Ready?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC – Free Report).
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.